This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2018 to 2023.
Companies that successfully challenge patents on branded drugs are granted six months of generic exclusivity.
Because first-on-market generics tend to sell at 70% or more of the price of the branded drug, the financial rewards stemming from
the market exclusivity granted for drug patent challenges can more than cover the subtantial costs of drug patent challenge and associated litigation.
The most successful patent challengers from 2018 to 2023 were
- Teva
- Arrow Intl
- Amneal
- Dr Reddys
- Mylan
- Accord
- Hetero Labs Ltd Iii
- Fresenius Kabi Usa
- Aurobindo Pharma
- Par Pharm Inc
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
